Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge provinces, Angola

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 437-443

  Plucinski, Mateusz M ^a   Talundzic, Eldin ^a   Morton, Lindsay ^a   Dimbu, Pedro Rafael ^b   Macaia, Aleixo Panzo ^c   Fortes, Filomeno ^b   Goldman, Ira ^a   Lucchi, Naomi ^a   Stennies, Gail ^a   MacArthur, John R ^a   Udhayakumar, Venkatachalam ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Ministry of Health   (United States)

^c Ministry of Health   (Angola)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ADEQUATE CLINICAL AND PARASITOLOGICAL RESPONSE; ANGOLA; ANTIMALARIAL ACTIVITY; ARTICLE; CHILD; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG TREATMENT FAILURE; FOLLOW UP; GENE; GENOTYPE; HUMAN; IN VIVO STUDY; INFANT; K13 PROPELLER GENE; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MICROBIAL GENE; MUTATION; OPEN STUDY; PARASITEMIA; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; REINFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; MALARIA, FALCIPARUM; MALE; PARASITOLOGY; TREATMENT FAILURE;

ANGOLA; ANTIMALARIALS; ARTEMISININS; CHILD; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; QUINOLINES; TREATMENT FAILURE;

EID: 84920119702     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04181-14     Document Type: Article

References (35)

1. World Health Organization. 2012. Guidelines for the treatment of malaria. World Health Organization, Geneva, Switzerland.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455-467. http://dx.doi.org/10.1056/NEJMoa0808859.
3. Wongsrichanalai C, Meshnick SR. 2008. Declining artesunatemefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 14:716-719. http://dx.doi.org/10.3201 /eid1405.071601.
4. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 Study Consortium. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620. http://dx.doi.org/10.1056/NEJMc0805011.
5. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F. 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379: 1960-1966. http://dx.doi.org/10.1016/S0140-6736(12)60484-X.
6. Satimai W, Sudathip P, Vijaykadga S, Khamsiriwatchara A, Sawang S, Potithavoranan T, Sangvichean A, Delacollette C, Singhasivanon P, Kaewkungwal J, Lawpoolsri S. 2012. Artemisinin resistance containment project in Thailand. II. Responses to mefloquine-artesunate combination therapy among falciparum malaria patients in provinces bordering Cambodia. Malar J 11:300. http://dx.doi.org/10.1186/1475-2875-11-300.
7. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, Al Saai S, Phyo AP, Moo CL, Lwin KM, McGready R, Ashley E, Imwong M, Stepniewska K, Yi P, Dondorp AM, Mayxay M, Newton PN, White NJ, Nosten F, Ferdig MT, Anderson TJ. 2012. A major genome region underlying artemisinin resistance in malaria. Science 336:79-82. http: //dx.doi.org/10.1126/science.1215966.
8. Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, Fukuda MM, Nosten F, Noedl H, Imwong M, Bethell D, Se Y, Lon C, Tyner SD, Saunders DL, Socheat D, Ariey F, Phyo AP, Starzengruber P, Fuehrer HP, Swoboda P, Stepniewska K, Flegg J, Arze C, Cerqueira GC, Silva JC, Ricklefs SM, Porcella SF, Stephens RM, Adams M, Kenefic LJ, Campino S, Auburn S, MacInnis B, Kwiatkowski DP, Su XZ, White NJ, Ringwald P, Plowe CV. 2013. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A 110: 240-245. http://dx.doi.org/10.1073/pnas.1211205110.
9. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50-55. http://dx.doi.org/10.1038/nature12876.
10. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria.NEngl J Med 371:411-423. http://dx.doi.org/10.1056/NEJMoa1314981.
11. Van Hong N. 2014. Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam. Emerg Infect Dis 20: 1199-1202. http://dx.doi.org/10.3201/eid2007.140155.
12. World Health Organization. 2009. Methods for surveillance of antimalarial drug efficacy. World Health Organization, Geneva, Switzerland.
13. Nzila A, Okombo J, Ohuma E, Al-Thukair A. 2012. Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine. J Antimicrob Chemother 67:2309-2315. http://dx.doi.org/10 .1093/jac/dks252.
14. Guthmann J, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, Kyomuhendo J, Francis M, Noël F, Mulemba M. 2006. High efficacy of two artemisinin-based combinations (artesunate+ amodiaquine and artemether + lumefantrine) in Caala, Central Angola.AmJ Trop Med Hyg 75:143.
15. Lucchi NW, Narayanan J, Karell MA, Xayavong M, Kariuki S, DaSilva AJ, Hill V, Udhayakumar V. 2013. Molecular diagnosis of malaria by photo-induced electron transfer fluorogenic primers: PET-PCR. PLoS One 8:e56677. http://dx.doi.org/10.1371/journal.pone.0056677.
16. Anderson TJ, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, Bockarie M, Mokili J, Mharakurwa S, French N, Whitworth J, Velez ID, Brockman AH, Nosten F, Ferreira MU, Day KP. 2000. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol 17:1467-1482. http://dx.doi.org/10.1093/oxfordjournals.molbev.a026247.
17. Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP. 1999. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 119:113-125. http://dx.doi .org/10.1017/S0031182099004552.
18. McCollum AM, Mueller K, Villegas L, Udhayakumar V, Escalante AA. 2007. Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother 51:2085-2091. http://dx.doi.org/10.1128/AAC.01228-06.
19. Griffing SM, Mixson-Hayden T, Sridaran S, Alam MT, McCollum AM, Cabezas C, Marquino Quezada W, Barnwell JW, De Oliveira AM, Lucas C, Arrospide N, Escalante AA, Bacon DJ, Udhayakumar V. 2011. South American Plasmodium falciparum after the malaria eradication era: clonal population expansion and survival of the fittest hybrids. PLoS One 6:e23486. http://dx.doi.org/10.1371/journal.pone.0023486.
20. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, Rosenthal PJ, Dorsey G. 2006. Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg 75:836-842.
21. Shaukat AM, Gilliams EA, Kenefic LJ, Laurens MB, Dzinjalamala FK, Nyirenda OM, Thesing PC, Jacob CG, Molyneux ME, Taylor TE. 2012. Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment. Malar J 11:1-6. http://dx.doi.org/10 .1186/1475-2875-11-1.
22. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S. 2004. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364:438-447. http://dx.doi.org/10 .1016/S0140-6736(04)16767-6.
23. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, Petzold M, Premji Z, Gil JP, Bjorkman A, Martensson A. 2013. Temporal trends of molecular markers associated with artemetherlumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar J 12:103. http://dx.doi.org/10.1186/1475-2875-12-103.
24. Falade C, Makanga M, Premji Z, Ortmann C-E, Stockmeyer M, de Palacios PI. 2005. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 99:459-467. http://dx.doi.org/10.1016/j.trstmh.2004.09.013.
25. Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, Walter V, Beck H-P, Marrast A-C, Cousin M. 2011. Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg 85:793. http://dx.doi.org/10.4269/ajtmh.2011.11-0069.
26. Nambozi M, Van Geertruyden J-P, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D'Alessandro U. 2011. Safety and efficacy of dihydroartemisinin-piperaquine versus artemetherlumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J 10:50. http://dx.doi.org/10.1186 /1475-2875-10-50.
27. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, Dorsey G, Janssens B, Mayxay M, Newton P, Singhasivanon P. 2009. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4:e6358. http://dx.doi.org/10.1371/journal.pone.0006358.
28. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J. 2005. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 365:1467-1473. http://dx.doi.org/10.1016 /S0140-6736(05)66416-1.
29. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, Björkman A. 2011. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 52:873-882. http://dx.doi.org/10.1093/cid/cir066.
30. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. 2009. Artemisininbased combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009:CD007483. http://dx.doi.org/10.1002/14651858 .CD007483.pub2.
31. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D. 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 57:253-262. http://dx.doi.org/10.1046/j.1365-2125.2003 .02004.x.
32. Ezzet F, Mull R, Karbwang J. 1998. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether- benflumetol) in malaria patients. Br J Clin Pharmacol 46:553-561.
33. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kamya MR, Tappero JW, Greenhouse B. 2014. Comparative impacts over 5 years of artemisinin-based combination therapies on P. falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis 210: 344-353. http://dx.doi.org /10.1093/infdis/jiu141.
34. Mbogo GW, Nankoberanyi S, Tukwasibwe S, Baliraine FN, Nsobya SL, Conrad MD, Arinaitwe E, Kamya M, Tappero J, Staedke SG. 2014. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda.Am J Trop Med Hyg 91:54-61. http://dx.doi.org/10.4269/ajtmh.13-0647.
35. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Bjorkman A, Martensson A, Gil JP. 2013. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis 207:842-847. http://dx.doi .org/10.1093/infdis/jis747.